Ustekinumab, a monoclonal antibody against the common p40 subunit is a highly effective treatment for psoriasis, and the antibodies targeting the p19 subunit (guselkumab, tildrakizumab and risankizumab) also show promising impact for symptom amelioration [1,26]. This evidence concerns the gene IL23A and psoriasis.